Seattle Cellular Therapy Summit: Patient-Centered Approach to Improve Outcomes

Seattle, WA US
August 4, 2023 to August 5, 2023

This CME-accredited activity, “Seattle Cellular Therapy Summit (SCTS): Patient-Centered Approach to Improve Outcomes”, features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. 

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
  • Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
  • Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology fellows
  • Oncology nurses
  • NPs/PAs
  • Oncology pharmacists

 

Hotel Information

Grand Hyatt Seattle

A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment. 

To receive the discounted rate, please reserve your room by Friday, July 14, 2023, by visiting the link below:

www.hyatt.com/en-US/group-booking/

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

You may also be interested in

Best of ASCO 2023, Minneapolis

This CME-accredited oncology conference, Best of ASCO 2023, Minneapolis, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.  
2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice

This CME-accredited activity 2023 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukem
Course summary
Available credit: 
  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.
Course opens: 
03/10/2023
Course expires: 
11/05/2023
Event starts: 
08/04/2023 - 3:15pm PDT
Event ends: 
08/05/2023 - 4:15pm PDT
Cost:
$300.00
Add to calendar: 

Conference Co-Chairs: Dr. Krish Patel, MD, and Dr. Mazyar Shadman, MD, MPH

(Preliminary schedule)

Day 1 - August 04, 2023

Times listed are in Pacific Standard Time (PST)
 

02:30 PM to 03:00 PM                        Registration, Exhibits, & Networking

03:00 PM to 03:15 PM                        Welcome & Introductions by co-chairs Dr. Krish Patel & Dr. Mazyar Shadman

03:15 PM to 05:15 PM                        Session I: Updates on Approved CAR T-Cell Therapies  

Moderators: Krish Patel, MD, & Mazyar Shadman, MD, MPH       

03:15 PM to 03:40 PM                        Updates in CAR T-cell Therapy in Lymphoma -David Maloney, MD, PhD

03:40 PM to 04:05 PM                        Updates in CAR T-cell Therapy in Myeloma -Kumar, Shaji, MD

04:05 PM to 04:30 PM                        Updates in CAR T-cell Therapy in ALL -Richard Maziarz, MD

04:30 PM to 05:15 PM                        Panel discussion with Krishna Komanduri, MD, Krish Patel, MD, & Mazyar Shadman, MD, MPH 

05:15 PM to 06:15 PM                        Abstract Session with faculty discussants: Krishna Komanduri, MD, Shaji Kumar, MD, & invited junior faculty (this is a non-CME activity)

 

 

Day 2 - August 05, 2023

Times listed are in Pacific Standard Time (PST)
 

07:00 AM to 07:55 AM                        Registration, Breakfast, & Exhibits

08:00 AM to 10:15 AM                        Session II: Debates in DLBCL and FL

Moderators: Mazyar Shadman, MD, MPH, & Richard Maziarz, MD

08:00 AM to 08:10 AM                        Case presentation: Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

08:10 AM to 08:25 AM                        DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of CAR T -Olalekan O. Oluwole, MBBS, MD

08:25 AM to 08:40 AM                        DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Auto-HSCT -Mazyar Shadman, MD, MPH       

08:40 AM to 08:55 AM                        DLBCL debate: CAR T versus Auto-HSCT versus Non-cellular Therapy – in favor of Non-cellular Therapy -Tycel Phillips, MD

08:55 AM to 09:10 AM                        Discussion

09:10 AM to 09:20 AM                        Case presentation: Relapsed/Refractory Follicular Lymphoma (FL) 

09:20 AM to 09:35 AM                        FL debate: CAR T versus Mosen versus Other – in favor of CAR T -Matthew Ulrickson, MD

09:35 AM to 09:50 AM                        FL debate: CAR T versus Mosen versus Other – in favor of Mosen -Nadia Khan, MD

09:50 AM to 10:05 AM                        FL debate: CAR T versus Mosen versus Other –in favor of Other -Chaitra Ujjani, MD

10:05 AM to 10:15 AM                        Discussion

10:15 AM to 10:30 AM                        Break & Exhibits

10:30 AM to 12:15 PM                        Session III: Debates in MCL and Myeloma    

Moderators: Nadia Khan, MD, & Krishna Komanduri, MD

10:30 AM to 10:40 AM                        Case presentation: Relapsed/Refractory Mantle Cell Lymphoma (MCL) -Julia Parker DRNP, AGNP-C

10:40 AM to 10:55 AM                        MCL debate: CAR T versus BTKi – in favor of CAR T -Matt Lunning, DO

10:55 AM to 11:10 AM                        MCL debate: CAR T versus BTKi – in favor of BTKi -Alexey Danilov, MD

11:10 AM to 11:20 AM                        Case presentation: Relapsed/Refractory Multiple Myeloma

11:20 AM to 11:35 AM                        Myeloma debate: CAR T versus Teclistimab – in favor of CAR T -Swathi Namburi, MD

11:35 AM to 11:50 AM                        Myeloma debate: CAR T versus Teclistimab – in favor of Teclistimab -Rahul Banerjee, MD

11:50 AM to 12:15 PM                        Discussion 

12:15 PM to 01:15 PM                        Lunch & Exhibits

01:15 PM to 02:00 PM                        Session IV: Addressing Barriers to Cellular Therapy

Moderator: TBA

01:15 PM to 01:30 PM                        Case presentation: Patient Barriers to Cellular Therapy -Samuel Jonas, MSW, and Sonia Glennie, ARNP MSN OCN

01:30 PM to 01:45 PM                        Allogeneic Cell Therapy: Glimpse of the Future? -Krish Patel, MD

01:45 PM to 02:00 PM                        Panel discussion with David Aboulafia, MD, Mazyar Shadman, MD, MPH, Krish Patel, MD, & Sherry X. Hu, MD, PhD

02:00 PM to 02:15 PM                        Break & Exhibits

02:15 PM to 03:30 PM                        Session V: Cellular Therapy in Leukemias

Moderators: Richard Maziarz, MD, & Melody Smith, MD, MS

02:15 PM to 02:30 PM                        Bispecific Antibody and CAR T Therapy in ALL - What is the right sequence? -Ryan Cassaday, MD

02:30 PM to 02:45 PM                        Cellular Therapy in CAR T and CLL -Tanya Siddiqi, MD

02:45 PM to 03:00 PM                        Cellular Therapy in AML/MDS: Emerging Data -Hany Elmariah, MD

03:00 PM to 03:15 PM                        Cellular Therapy in AML: Overcoming Challenges -Naval Daver, MD

03:15 PM to 03:30 PM                        Discussion

03:30 PM to 04:15 PM                        Session VI: Cellular Therapy in Solid Tumors

Moderator: Sid Devarakonda, MBBS MD

03:30 PM to 03:45 PM                        Cellular Therapy in Solid Tumors: Emerging Data -Kedar Kirtane, MD

03:45 PM to 04:00 PM                        Cellular Therapy in Solid Tumors: Overcoming Challenges -Kelly Paulson, MD, PhD

04:00 PM to 04:15 PM                        Discussion  

04:15 PM to 04:20 PM                        Concluding remarks & announcements

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States

A limited number of rooms have been reserved at the Grand Hyatt Seattle for participants and exhibitors of the Seattle Cellular Therapy Summit at a discounted rate of $249/night for single occupancy. This rate is exclusive of taxes and Seattle Tourism Assessment. 

Please reserve your room by Friday, July 14, 2023, by clicking the link below.

https://www.hyatt.com/en-US/group-booking/SEAGH/G-BYTA

 

Course Director(s)

Krish Patel, MD

has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Moderator(s)

Nadia Khan, MD

has a financial relationship (Independent contractor) with PCYC;.
has a financial relationship (Independent contractor) with Beigene ;.
has a financial relationship (Independent contractor) with Adaptive;.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Optum Health;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.

Krish Patel, MD

has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with Abbvie;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
Planner(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Rahul Banerjee, MD, FACP

has a financial relationship (Independent contractor) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Curio Science;.
has a financial relationship (Independent contractor) with Sanofi Pasteur;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with SparkCures;.
has a financial relationship (Independent contractor) with Clearview Healthcare Partners;.
has a financial relationship (Grant Or Contract) with i3 Health;.
has a financial relationship (Grant Or Contract) with Pack Health;.
has a financial relationship (Grant Or Contract) with Clinical Care Options;.
has a financial relationship (Independent contractor) with Guidepoint Global;.

Ryan Cassaday, MD

has a financial relationship (Independent contractor) with Amgen;.
has a financial relationship (Other) with Autolus;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Grant Or Contract) with Kite;.
has a financial relationship (Grant Or Contract) with Vanda;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Stock Options) with Seagen;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Independent contractor) with Jazz;.
has a financial relationship (Employment) with Seagen;.
has a financial relationship (Grant Or Contract) with Servier;.

Alexey Danilov, MD, PhD

has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Grant Or Contract) with MEI;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Grant Or Contract) with Nurix;.

Naval Daver, MD

has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Other) with Trillium;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Other) with Celgene;.
has a financial relationship (Other) with KITE;.
has a financial relationship (Grant Or Contract) with Hanmi;.
has a financial relationship (Grant Or Contract) with Glycomimmetics;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Astellas;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Other) with Jazz;.
has a financial relationship (Grant Or Contract) with Trillium;.
has a financial relationship (Other) with Agios;.
has a financial relationship (Grant Or Contract) with Novimmune;.
has a financial relationship (Other) with Bristol-Meyers Squibb;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Immunogen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Other) with Shattuck Labs;.
has a financial relationship (Grant Or Contract) with FATE Therapeutics;.
has a financial relationship (Other) with Daiichi-Sankyo;.
has a financial relationship (Other) with Servier;.
has a financial relationship (Grant Or Contract) with Bristol-Meyers Squibb;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Grant Or Contract) with Servier;.
has a financial relationship (Other) with Arog;.
has a financial relationship (Grant Or Contract) with Immunogen;.
has a financial relationship (Other) with Syndax;.
has a financial relationship (Other) with Stemline/Menarini;.
has a financial relationship (Grant Or Contract) with Trovagene;.
has a financial relationship (Grant Or Contract) with KITE;.
has a financial relationship (Other) with Gilead;.
has a financial relationship (Grant Or Contract) with Daiichi-Sankyo;.

Sherry Hu

has no relevant financial relationships to disclose at this time.

Samuel Jonas, MSW

has no relevant financial relationships to disclose at this time.

Nadia Khan, MD

has a financial relationship (Independent contractor) with PCYC;.
has a financial relationship (Independent contractor) with Beigene ;.
has a financial relationship (Independent contractor) with Adaptive;.

Kedar Kirtane, MD

has a financial relationship (Stock) with Shockwave Medical;.
has a financial relationship (Stock) with Oncternal Therapeutics;.
has a financial relationship (Stock) with Seattle Genetics;.
has a financial relationship (Travel) with A2Bio Therapeutics;.

Krishna Komanduri, MD

has a financial relationship (Independent contractor) with Iovance;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Independent contractor) with Cargo Therapeutics;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Avacta Therapeutics;.
has a financial relationship (Independent contractor) with CRISPR Therapeutics;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with Optum Health;.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Matthew Lunning, Matt Lunning, D.O., F.A.C.P.

has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Astellas;.
has a financial relationship (Grant Or Contract) with Curis;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Morphosys;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Astra Zeneca;.
has a financial relationship (Professional Services) with CRISPR;.
has a financial relationship (Professional Services) with Fate Therapetuics;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with Miltenyi;.
has a financial relationship (Professional Services) with Nurix;.
has a financial relationship (Professional Services) with SeaGen;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with EUSA;.
has a financial relationship (Professional Services) with InstilBio;.
has a financial relationship (Professional Services) with Loxo;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with Acrotech;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with GenMab;.
has a financial relationship (Professional Services) with Kite;.

David Maloney, MD, PhD

has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Interius;.
has a financial relationship (Other) with Celgene;.
has a financial relationship (Other) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with Juno therapeutics;.
has a financial relationship (Patent) with Juno Therapeutics/BMS;.
has a financial relationship (Other) with Chimeric Therapeutics;.
has a financial relationship (Other) with Gilead Sciences;.
has a financial relationship (Other) with Caribou Biosciences;.
has a financial relationship (Other) with Juno Therapeutics;.
has a financial relationship (Grant Or Contract) with Kite Pharna;.
has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.
has a financial relationship (Other) with ImmPACT Bio;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with Mustang Bio;.
has a financial relationship (Grant Or Contract) with Legend Biotech;.
has a financial relationship (Stock Options) with Navan Technologies;.
has a financial relationship (Other) with BMS;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Grant Or Contract) with Celgene;.
has a financial relationship (Stock Options) with A2 Biotherapeutics;.

Swathi Namburi, MD

has no relevant financial relationships to disclose at this time.

Krish Patel, MD

has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Professional Services) with Fate Therapeutics;.
has a financial relationship (Professional Services) with Lilly;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Professional Services) with Epizyme;.
has a financial relationship (Professional Services) with Janssen/Pharmacyclics;.
has a financial relationship (Professional Services) with Xencor;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caribou;.
has a financial relationship (Professional Services) with Kite;.
has a financial relationship (Professional Services) with ADC Therapeutics;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with Pfizer;.

Kelly Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.
has a financial relationship (Employment) with BMS;.

Chaitra Ujjani, MD

has a financial relationship (Independent contractor) with Pharmacyclics;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Eli Lilly;.
has a financial relationship (Independent contractor) with Atara;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Incyte;.

Available Credit

  • 8.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$300.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $300

Non-physician HCP (non-industry) - $200

Industry representatives - $1250

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.